ºñ¹Ð¹øÈ£
(°Ô½Ã¹° ÀÛ¼º½Ã ÀÔ·ÂÇÑ Æнº¿öµå¸¦ ÀÔ·ÂÇϼ¼¿ä)
HTML¾²±â
À̸§
¸µÅ©
÷ºÎÆÄÀÏ
¼öÁ¤¾ÈÇÔ
÷ºÎÆÄÀϼöÁ¤
÷ºÎÆÄÀÏ»èÁ¦
(
÷ºÎÆÄÀÏÀ» ¼öÁ¤ÇÏ°íÀÚ ÇÒ¶§¸¸)
Á¦¸ñ
³ë¹ÙƼ½º°¡ 2003³â 1¿ù 23ÀÏ ¹ßÇ¥ÇÑ ¿¬·Êº¸°í¼¿¡ µû¸£¸é, 2002³â ±Û¸®º¤ ¸ÅÃâÀº ÃÑ 6¾ï 1õ5¹é¸¸ ´Þ·¯ÀÔ´Ï´Ù. 2001³â 1¾ï 5õ3¹é¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» ÇÏ¿´À¸´Ï, Áö±Ý±îÁö ±Û¸®º¤ÀÇ ÃѸÅÃâÀº 7¾ï 6õ8¹é¸¸ ´Þ·¯ÀÌ°í ¿øÈ(¿À´Ã ȯÀ²: 1163.0000)·Î´Â 893,183,983,616 ¿ø Áï, ¾à 8õ 9¹é3½Ê¾ï¿øÀÔ´Ï´Ù. ³ë¹ÙƼ½º´Â ±Û¸®º¤ °³¹ß ºñ¿ëÀÌ ¾à 8¾ï ´Þ·¯¶ó°í ÁÖÀåÇÑ ¹Ù Àִµ¥, °øÀûÀÚ±ÝÀ̳ª ¼¼±ÝÇýÅÃÀ» ¹Þ¾Ò°í, 3»ó ÀÓ»ó½ÇÇèºñ°¡ µéÁö ¾Ê¾Ò´Ù´Â Á¡, Ưº°ÇÑ ¸¶ÄÉÆÃÀÌ ¾ø¾îµµ ȯÀÚ¿Í ¾ð·ÐÀ» ÅëÇØ È«º¸°¡ µÇ¾ú´Ù´Â Á¡ µîÀ» °í·ÁÇϸé ÀÌ¹Ì °³¹ßºñ ȸ¼ö¸¦ Çß´Ù°í ÇÒ ¼ö ÀÖ°Ú±º¿ä. 2002³â ±Û¸®º¤ ¸ÅÃâÀº 303%³ª Áõ°¡ÇÏ¿´°í ³ë¹ÙƼ½º Á¦Ç° °¡¿îµ¥ 5À§ ¸ÅÃâÀ» ±â·ÏÇÏ¿´½À´Ï´Ù. Èñ±ÍÁúº´ Ä¡·á¾àÀÌ ÀÌ·¸°Ô ³ôÀº ¸ÅÃâÀ» ±â·ÏÇÏ¿´´Ù´Â °ÍÀÌ ¹«¾ùÀ» ÀǹÌÇÏ´Â Áö´Â ³Ê¹«³ª ºÐ¸íÇÕ´Ï´Ù. ±Û¸®º¤ÀÇ 2002³â ¸ÅÃâ ÀÚ·á´Â http://www.novartis.com/downloads/annual_reports/press_release_full_year_results_2002.pdf À§ ÀÚ·á¿¡¼ ¹ßÃéÇÑ ³»¿ëÀÔ´Ï´Ù. Gleevec/Glivec, (+303%, US: +103%;) for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), continued to bring benefits to thousands of patients in more than 80 countries. Exceeding expectations, twelve-month sales topped CHF 953 million (USD 615 million), making it Novartis¡¯ fifth biggest product. Gleevec/Glivec has now been approved as first-line treatment in the US, EU and Switzerland, and major progress has been achieved on eimbursement, especially in the UK, Australia and New Zealand.
±Û¸®º¤ °¡°ÝÀÎÇÏ, ÀǾàÇ° °ø°ø¼º °È¸¦ À§ÇÑ °øµ¿´ëÃ¥À§¿øȸ
Korean Progressive Network
Jinbo.Net
No CopyRight, Just CopyLeft!!